This is a Phase 1, first-in-human open-label, dose-escalation and expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.

This is a Phase 1, first-in-human open-label, dose-escalation and expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors. This study will consist of a Dose-Escalation Stage and a Cohort-Expansion Stage for XL092 as single-agent therapy and in ICI combination therapy. Potential patients are required to come to the clinic for 8 hour days at the beginning of certain cycles for frequent blood draws. Along with 8 hours days, they will need to be seen weekly when first starting the investigational drug. Frequent blood testa will be involved to ensure patient safety along with frequent scans to see how their disease responses to treatment.